M&A
Agilent acquires digital pathology software company Proscia for $240M
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Agilent Technologies, Proscia
Date
Agilent Technologies announced the acquisition of Proscia, a digital pathology software company, in an all-cash transaction valued at $240 million upfront with an additional $30 million contingent on future performance milestones. The deal gives Agilent ownership of Proscia's Concentriq platform, which serves as a central operating layer for digital pathology, supporting clinical and life-sciences customers across the U.S. and Europe.
The acquisition directly impacts Agilent's pathology division and Proscia's integration team, as well as the 4,000+ laboratories, hospitals, and pharma companies currently using the Concentriq platform. Customers rely on the platform to manage images, data, and workflows, and it supports third-party AI applications for a range of clinical diagnosis and life-sciences research.
This acquisition strengthens Agilent's position in the fast-growing digital pathology market. Key implications include:
Monitor how Agilent integrates Proscia's team and technology, particularly the Concentriq platform, into its existing portfolio. The $30 million in performance milestones suggest specific growth targets for Proscia's customer base or revenue. Also watch for potential changes in the platform's third-party AI application support and any new partnerships or distribution agreements that may emerge from this acquisition.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
